查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2017229

梅毒免疫检测测定诊断市场：依产品类型、技术、检体类型和最终用户划分－2026-2032年全球市场预测

Syphilis Immunoassay Diagnostic Market by Product Type, Technology, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，梅毒免疫检测测定诊断市场价值将达到 5.7843 亿美元，到 2026 年将成长至 6.1181 亿美元，到 2032 年将达到 8.6744 亿美元，复合年增长率为 5.95%。

主要市场统计数据
基准年 2025 5.7843亿美元
预计年份：2026年 6.1181亿美元
预测年份 2032 8.6744亿美元
复合年增长率 (%) 5.95%

对现代医学实践中影响梅毒免疫检测测定诊断的临床、技术和操作驱动因素的演变进行了清晰而令人信服的阐述。

梅毒免疫检测测定诊断在公共卫生监测、临床决策和检查室现代化之间起着至关重要的作用。测量技术的进步、筛检建议的扩展以及对性行为感染预防公共卫生工作的重新重视，已将诊断流程从间歇性检测转变为在临床机构和社区内开展的综合性、持续性筛检。因此，诊断相关人员正在重新审视筹资策略、检查室流程和临床医生培训计划，以确保检测的及时性、准确性和实用性。

技术创新、检查室自动化以及对公共卫生优先事项的重新评估如何全面重塑梅毒免疫检测检测和服务提供。

梅毒免疫检测检测诊断领域正经历着变革性的转变，这主要得益于技术的成熟、操作的整合以及政策对性行为感染感染日益增长的关注。化学冷光和萤光免疫分析技术的创新提高了分析性能，使得早期检测和更可靠地区分既往感染与性行为感染成为可能。同时，照护现场设备和半自动分析仪的普及分散了检测能力，使诊所、社区支持计画和小规模检查室能够在不完全依赖中心实验室的情况下及时提供检测结果。

评估 2025 年美国关税调整对诊断供应链、筹资策略和检查室采购韧性的营运外溢效应。

美国将于2025年实施的关税调整，为诊断供应链和采购团队的营运规划带来了新的挑战。关税变化影响了进口组件和成品检测套组的单位成本，进而影响试剂和设备的采购决策，并改变了公立和私立检测实验室的库存策略。为此，采购经理们正在审查与供应商的合同，协商更长期的协议以规避价格波动风险，并探索建立双源采购机制以确保供应的连续性。

我们按产品、技术、检体和最终用户进行细分，以确定整个诊断环境中的采购因素、平台适用性和部署优先顺序。

在梅毒免疫检测领域，细緻的细分观点对于理解其应用模式、采购因素和产品开发重点至关重要。根据产品类型，相关人员将产品分为「仪器」、「试剂盒」和「软体」三类。仪器又细分为“全自动分析仪”、“照护现场（POC​​）设备”和“半全自动分析仪”，而试剂盒则细分为“品管试剂盒”、“即用型（RTU）试剂盒”和“试剂组”。这些分类指南资本投资规划。全自动分析仪通常安装在高通量检查室中，而即时检测设备则支援在诊所和社区医疗机构进行分散式筛检。即用型试剂盒透过最大限度地简化製备过程来支援分散式检查，而试剂组和品管试剂盒在品质保证计划中仍然发挥核心作用。

影响全球采购选择、监管环境和分销策略的区域诊断环境和实施实践。

区域趋势影响梅毒免疫检测测定诊断的需求、监管管道和分销策略。在美洲，临床筛检重点、现有检查室基础设施和支付机制影响自动化分析仪和分散式检查计划的采用，这些计划旨在扩大服务不足社区的检测覆盖范围。区域法规结构和报销模式推动新检测方法的商业化进程，并塑造製造商与公共卫生计画之间合作的机会。

梅毒免疫检测测定诊断领域的竞争趋势和供应商策略：强调平台合作、品质系统和服务主导差异化的重要性

梅毒免疫检测测定诊断领域的竞争格局呈现出大型多元化诊断公司和专业创新企业并存的局面。成熟的体外诊断试剂生产商持续投资于平台相容性、检测特异性和与实验室资讯系统的集成，而专注于照护现场的便捷性、快速出结果和简化试剂盒规格的公司则致力于提升检测效率。实验室设备供应商和试剂开发商之间的策略合作日益普遍，旨在提供整合解决方案，降低检查室和诊所采用这些方案的门槛。此外，契约製造和专业试剂供应商在确保关键检测组件的品质稳定性和供应连续性方面发挥着至关重要的作用。

为製造商和检查室管理人员提供可操作的策略重点，以增强梅毒免疫检测的韧性，加快其应用，并提高其临床效用。

产业领导者应采取积极主动的方式，在创新投资与务实的供应链和商业规划之间取得平衡。优先考虑与实验室资讯系统的互通性和无缝集成，将提高免疫检测结果的临床效用，并支援下游监测和报告。同时，製造商应扩展灵活的产品组合，以适应集中式检查室处理能力和分散式即时筛检（POC​​）的需求，从而在不影响分析完整性的前提下，实现广泛的应用。

我们透过透明、多方面的研究途径提供可操作的诊断信息，该方法结合了相关利益者访谈、监管分析和技术审查。

本研究整合了对实验室管理人员、采购负责人、临床用户和行业高管的访谈所得出的见解，并辅以对监管指南、同行评审文献和製造商技术文件的二次分析。主要研究着重于了解实际操作情况、采购决策者以及设备和检测方法的实际应用经验，而二级资讯来源提供了有关技术性能特征、监管路径和实施案例的背景资讯。

将梅毒检测诊断创新转化为更便捷的检测、更高的可靠性和更大的公共卫生影响的关键见解和策略挑战。

总之，梅毒免疫检测检测诊断领域正处于转折点，技术进步、营运现代化和政策关注的交汇正在重塑检测方式。儘管检测技术的改进和分散式检查的普及提高了诊断的可及性并缩短了诊断时间，但供应炼和监管方面的考虑正在影响产品的开发、生产和采购方式。相关人员，将更有能力将诊断能力转化为可衡量的公共卫生和临床成果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 梅毒免疫检测测定诊断市场：依产品类型划分

  • 装置
    • 全自动分析仪
    • 即时检测设备
    • 半自动分析仪
  • 成套工具
    • 控制套件
    • 即用型套件
    • 试剂组
  • 软体

第九章：梅毒免疫检测测定诊断市场：依技术划分

  • 化学冷光免疫检测
  • 酵素免疫分析法
  • 萤光免疫分析

第十章：以检体类型分類的梅毒免疫检测测定诊断市场

  • 血清/血浆
  • 全血

第十一章 梅毒免疫检测测定诊断市场：依最终用户划分

  • 血库
  • 诊所
  • 测试机构
  • 医院

第十二章 梅毒免疫检测测定诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 梅毒免疫检测诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 梅毒免疫检测测定诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国梅毒免疫检测测定诊断市场

第十六章：中国梅毒免疫检测检测诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-036CEF508599

The Syphilis Immunoassay Diagnostic Market was valued at USD 578.43 million in 2025 and is projected to grow to USD 611.81 million in 2026, with a CAGR of 5.95%, reaching USD 867.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 578.43 million
Estimated Year [2026] USD 611.81 million
Forecast Year [2032] USD 867.44 million
CAGR (%) 5.95%

A clear and compelling orientation to the evolving clinical, technological, and operational drivers shaping syphilis immunoassay diagnostics in contemporary healthcare settings

Syphilis immunoassay diagnostics occupy a critical intersection of public health surveillance, clinical decision-making, and laboratory modernization. Advances in assay technologies, expanded screening recommendations, and renewed public health emphasis on sexually transmitted infection control have elevated diagnostic workflows from episodic testing to sustained screening integrated across clinical and community settings. As a result, diagnostic stakeholders are recalibrating procurement strategies, laboratory processes, and clinician education programs to ensure testing is timely, accurate, and actionable.

Over the past several years, diagnostic providers have moved toward consolidated testing pathways that prioritize sensitivity and specificity while reducing time-to-result and hands-on operator time. This shift is evident in the uptake of automated platforms, the refinement of kit formats, and the broader integration of immunoassay outputs into electronic health records and surveillance systems. Looking ahead, resilience of supply chains, regulatory alignment, and interoperability of diagnostic data will increasingly determine how effectively syphilis testing supports prevention, treatment initiation, and population-level control efforts.

How technological innovation, laboratory automation, and renewed public health priorities are collectively reshaping syphilis immunoassay testing and service delivery

The landscape for syphilis immunoassay diagnostics is undergoing transformative shifts driven by technological maturation, operational consolidation, and heightened policy focus on sexually transmitted infections. Innovations in chemiluminescence and fluorescence immunoassay technologies have improved analytical performance, enabling earlier detection and more reliable differentiation between past and active infections. Concurrently, the proliferation of point-of-care devices and semi-automated analyzers is decentralizing testing capacity, allowing clinics, community outreach programs, and smaller laboratories to deliver timely results without full reliance on centralized reference labs.

Operationally, laboratories are prioritizing automation and workflow integration to reduce manual handling, lower error rates, and increase throughput. This trend is reinforced by health systems pursuing diagnostic stewardship-optimizing test ordering and result interpretation to improve clinical utility. At the policy level, renewed public health investment in STI screening programs and clearer clinical guidelines are expanding screening penetrance. Taken together, these shifts are creating a more responsive diagnostic ecosystem where performance, speed, and ease of use are paramount, and where strategic alignment across manufacturers, laboratories, and public health agencies will determine adoption trajectories.

Assessing the operational ripple effects of United States tariff adjustments in 2025 on diagnostic supply chains, sourcing strategies, and laboratory procurement resilience

The introduction of tariff adjustments in the United States in 2025 has introduced a new dimension of operational planning for diagnostic supply chains and procurement teams. Tariff changes affect the unit cost of imported components and finished assay kits, influence sourcing decisions for reagents and instruments, and alter inventory strategies across both commercial and public laboratories. In response, procurement leaders are reassessing supplier contracts, negotiating longer-term terms to hedge price volatility, and exploring dual-sourcing arrangements to protect continuity of supply.

Beyond immediate cost considerations, tariffs are accelerating conversations about nearshoring manufacturing and expanding domestic capacity for critical assay components. Manufacturers are evaluating the trade-offs between relocated production and the capital and regulatory investments required to establish compliant assembly and reagent production within domestic jurisdictions. For clinical laboratories and health systems, the practical implications include extended lead times for some imported instruments, a greater emphasis on inventory visibility, and a need for flexible procurement frameworks that can accommodate price pass-through while preserving access to essential diagnostics. These dynamics underscore the importance of proactive supply chain analytics and cross-functional coordination among procurement, clinical leadership, and manufacturer partners.

Deconstructing product, technology, sample, and end-user segmentations to reveal procurement drivers, platform fit, and deployment priorities across diagnostic settings

A granular segmentation view is essential for understanding adoption patterns, procurement drivers, and product development priorities across the syphilis immunoassay space. Based on Product Type, stakeholders differentiate offerings into Instruments, Kits, and Software, with Instruments further categorized as Automated Analyzer, Point Of Care Device, and Semi-Automated Analyzer, and Kits disaggregated into Control Kits, Ready-To-Use Kits, and Reagent Kits. These distinctions inform capital planning, with automated analyzers often anchored in high-throughput laboratories while point-of-care devices enable distributed screening in clinics and outreach settings. Ready-to-use kits support decentralized testing by minimizing preparation complexity, whereas reagent kits and control kits remain central to quality assurance programs.

Based on Technology, testing modalities such as Chemiluminescence Immunoassay, Enzyme-Linked Immunosorbent Assay, and Fluorescence Immunoassay drive differences in analytical sensitivity, workflow complexity, and platform compatibility. The choice of technology influences not only diagnostic performance but also laboratory staffing, instrument footprint, and integration requirements. Based on Sample Type, distinctions between Serum Plasma and Whole Blood specimen handling affect pre-analytical workflows, collection site logistics, and the feasibility of point-of-care screening in community and remote settings. Finally, based on End User, the landscape spans Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals, each with distinct procurement cycles, quality systems, and decision criteria. Understanding these layered segmentations enables manufacturers and providers to tailor product design, regulatory strategies, and commercial approaches to the operational realities of their target end users.

Regional diagnostic landscapes and deployment realities shaping procurement choices, regulatory approaches, and distribution strategies across global territories

Regional dynamics shape demand profiles, regulatory pathways, and distribution strategies for syphilis immunoassay diagnostics. In the Americas, clinical screening priorities, established laboratory infrastructure, and payer mechanisms influence the adoption of automated analyzers as well as decentralized testing initiatives that aim to broaden access in underserved communities. The region's regulatory frameworks and reimbursement models drive the commercialization timelines for newer assay formats and shape collaboration opportunities between manufacturers and public health programs.

Europe, Middle East & Africa present a heterogeneous set of challenges and opportunities, where advanced diagnostic networks in some markets coexist with limited laboratory capacity in others. This diversity necessitates flexible product portfolios that can span high-throughput central labs to robust, low-maintenance point-of-care systems suitable for resource-constrained environments. Meanwhile, Asia-Pacific is characterized by rapid modernization of laboratory infrastructure, strong domestic manufacturing capabilities in several countries, and expanding public health screening initiatives. Across all regions, distribution partnerships, local regulatory compliance, and the ability to offer training and technical support are decisive factors that influence uptake and long-term utilization of diagnostic solutions.

Competitive dynamics and supplier strategies in syphilis immunoassay diagnostics demonstrating the importance of platform partnerships, quality systems, and service-driven differentiation

The competitive environment in syphilis immunoassay diagnostics reflects a blend of large, diversified diagnostics firms and specialized innovators. Established in-vitro diagnostics manufacturers continue to invest in platform compatibility, assay specificity, and integration with laboratory information systems, while niche companies focus on point-of-care convenience, rapid turnaround, and simplified kit formats. Strategic partnerships between instrument vendors and reagent developers are increasingly common, aiming to offer bundled solutions that reduce implementation friction for laboratories and clinics. In addition, contract manufacturers and specialized reagent suppliers play a pivotal role in ensuring consistent quality and supply continuity for core assay components.

For purchasers and partners, evaluation criteria often prioritize proven analytical performance, regulatory clearances in target geographies, post-market support capabilities, and a demonstrated track record on quality systems. Companies that combine robust technical documentation, accessible service networks, and flexible commercial terms are better positioned to meet the diverse needs of hospitals, diagnostic laboratories, clinics, and blood banks. As competition intensifies, differentiation increasingly hinges on end-to-end service models that extend beyond the instrument or kit to encompass training, maintenance, and data interoperability services.

Actionable strategic priorities for manufacturers and laboratory leaders to strengthen resilience, accelerate adoption, and enhance clinical utility of syphilis immunoassays

Industry leaders should adopt a proactive posture that balances innovation investment with pragmatic supply chain and commercial planning. Prioritizing interoperability and seamless integration with laboratory information systems will enhance the clinical utility of immunoassay results and support downstream surveillance and reporting. Simultaneously, manufacturers should expand flexible product configurations that address both centralized laboratory throughput and decentralized point-of-care screening, enabling broad access without sacrificing analytical integrity.

Leaders must also institute resilient procurement and manufacturing strategies that mitigate the impact of trade policy fluctuations. This includes diversifying supplier bases, assessing nearshoring options where feasible, and implementing inventory analytics to reduce stockouts. On the commercial front, targeted engagement with public health programs and care networks can accelerate adoption by aligning product offerings with screening guidelines and reimbursement frameworks. Finally, investing in clinician and laboratory education will enhance appropriate test utilization and result interpretation, thereby maximizing the clinical value of syphilis immunoassay diagnostics.

A transparent multi-source research approach combining stakeholder interviews, regulatory analysis, and technical review to deliver actionable diagnostic intelligence

This research synthesizes insights from primary interviews with laboratory directors, procurement officers, clinical users, and industry executives, complemented by secondary analysis of regulatory guidance, peer-reviewed literature, and manufacturer technical documentation. Primary engagement focused on capturing operational realities, procurement decision drivers, and real-world experiences with instruments and assay formats, while secondary sources provided context on technology performance characteristics, regulatory pathways, and implementation case studies.

Analytic methods included qualitative thematic analysis of stakeholder interviews, cross-comparison of product specifications and regulatory clearances, and scenario mapping of supply chain impacts. Wherever applicable, findings were triangulated across multiple information sources to validate themes and identify divergences between clinical practice and manufacturer claims. Confidentiality protocols were observed for all primary contributors, and the research approach emphasized transparency in assumptions and limitations to ensure the findings are actionable for decision-makers across industry and healthcare settings.

Key takeaways and strategic imperatives to convert diagnostic innovation into improved access, reliability, and public health impact for syphilis testing

In conclusion, the syphilis immunoassay diagnostic arena is at an inflection point where technological advances, operational modernization, and policy attention converge to reshape testing pathways. Improved assay technologies and the expansion of decentralized testing are enhancing access and shortening time-to-diagnosis, while supply chain and regulatory considerations are influencing how products are developed, manufactured, and procured. Stakeholders who align product strategies with end-user workflows, invest in integration and support, and build supply chain resilience will be best positioned to translate diagnostic capability into measurable public health and clinical outcomes.

Sustained progress will require collaboration across manufacturers, clinical laboratories, public health agencies, and procurement bodies to ensure that advances in assay performance are matched by practical implementation support. By focusing on interoperability, quality assurance, and accessible deployment models, the diagnostic community can strengthen syphilis screening programs and improve care pathways for affected populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Syphilis Immunoassay Diagnostic Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Analyzer
    • 8.1.2. Point Of Care Device
    • 8.1.3. Semi-Automated Analyzer
  • 8.2. Kits
    • 8.2.1. Control Kits
    • 8.2.2. Ready-To-Use Kits
    • 8.2.3. Reagent Kits
  • 8.3. Software

9. Syphilis Immunoassay Diagnostic Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme-Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay

10. Syphilis Immunoassay Diagnostic Market, by Sample Type

  • 10.1. Serum Plasma
  • 10.2. Whole Blood

11. Syphilis Immunoassay Diagnostic Market, by End User

  • 11.1. Blood Banks
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals

12. Syphilis Immunoassay Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Syphilis Immunoassay Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Syphilis Immunoassay Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Syphilis Immunoassay Diagnostic Market

16. China Syphilis Immunoassay Diagnostic Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Beckman Coulter, Inc.
  • 17.7. Becton Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. bioMerieux SA
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Ortho Clinical Diagnostics, LLC
  • 17.13. Siemens Healthineers AG
  • 17.14. Thermo Fisher Scientific Inc.
  • 17.15. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)